{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:07:44Z","timestamp":1785769664692,"version":"3.56.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Wu Jieping Medical Foundation Special Fund for Clinical Research","award":["320.6750.2021-06-5"],"award-info":[{"award-number":["320.6750.2021-06-5"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02983-5","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T18:05:54Z","timestamp":1750356354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["PTX3 as a diagnostic and prognostic biomarker in lung adenocarcinoma: a comprehensive analysis"],"prefix":"10.1007","volume":"16","author":[{"given":"Shaobo","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Haishaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"issue":"1","key":"2983_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2983_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-024-00551-9","volume":"10","author":"LEL Hendriks","year":"2024","unstructured":"Hendriks LEL, Remon J, Faivre-Finn C, Garassino MC, Heymach JV, Kerr KM, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2024;10(1):1\u201322.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"2983_CR3","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.3390\/ijms24032859","volume":"24","author":"A Forder","year":"2023","unstructured":"Forder A, Zhuang R, Souza VGP, Brockley LJ, Pewarchuk ME, Telkar N, et al. Mechanisms contributing to the comorbidity of COPD and lung Cancer. Int J Mol Sci. 2023;24(3):2859.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2983_CR4","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1158\/1940-6207.CAPR-15-0400","volume":"9","author":"H Kadara","year":"2016","unstructured":"Kadara H, Scheet P, Wistuba II, Spira AE. Early events in the molecular pathogenesis of lung Cancer. Cancer Prev Res (Phila). 2016;9(7):518\u201327.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"6","key":"2983_CR5","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1055\/s-0042-1757885","volume":"43","author":"E Lee","year":"2022","unstructured":"Lee E, Kazerooni EA. Lung Cancer screening. Semin Respir Crit Care Med. 2022;43(6):839\u201350.","journal-title":"Semin Respir Crit Care Med"},{"issue":"4","key":"2983_CR6","doi-asserted-by":"publisher","first-page":"6214","DOI":"10.18632\/aging.202504","volume":"13","author":"J Ning","year":"2021","unstructured":"Ning J, Ge T, Jiang M, Jia K, Wang L, Li W, et al. Early diagnosis of lung cancer: which is the optimal choice? Aging. 2021;13(4):6214\u201327.","journal-title":"Aging"},{"key":"2983_CR7","doi-asserted-by":"publisher","first-page":"104686","DOI":"10.1016\/j.ebiom.2023.104686","volume":"93","author":"MPA Davies","year":"2023","unstructured":"Davies MPA, Sato T, Ashoor H, Hou L, Liloglou T, Yang R, et al. Plasma protein biomarkers for early prediction of lung cancer. EBioMedicine. 2023;93:104686.","journal-title":"EBioMedicine"},{"issue":"2","key":"2983_CR8","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1152\/physrev.00016.2017","volume":"98","author":"C Garlanda","year":"2018","unstructured":"Garlanda C, Bottazzi B, Magrini E, Inforzato A, Mantovani A. PTX3, a humoral pattern recognition molecule, in innate immunity, tissue repair, and Cancer. Physiol Rev. 2018;98(2):623\u201339.","journal-title":"Physiol Rev"},{"issue":"30","key":"2983_CR9","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.1038\/s41388-019-0848-9","volume":"38","author":"M Rathore","year":"2019","unstructured":"Rathore M, Girard C, Ohanna M, Tichet M, Ben Jouira R, Garcia E, et al. Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)\/NF-\u03baB signaling pathway. Oncogene. 2019;38(30):5873\u201389.","journal-title":"Oncogene"},{"issue":"2","key":"2983_CR10","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1158\/0008-5472.CAN-20-1976","volume":"81","author":"CA Wills","year":"2021","unstructured":"Wills CA, Liu X, Chen L, Zhao Y, Dower CM, Sundstrom J, et al. Chemotherapy-Induced upregulation of small extracellular Vesicle-Associated PTX3 accelerates breast Cancer metastasis. Cancer Res. 2021;81(2):452\u201363.","journal-title":"Cancer Res"},{"key":"2983_CR11","doi-asserted-by":"publisher","first-page":"4652483","DOI":"10.1155\/2020\/4652483","volume":"2020","author":"T Hu","year":"2020","unstructured":"Hu T, Qiao L, Li H, Ren H, Ning Q, Zhou H, et al. Pentraxin 3 (PTX-3) levels in Bronchoalveolar lavage fluid as a lung Cancer biomarker. Dis Markers. 2020;2020:4652483.","journal-title":"Dis Markers"},{"issue":"W1","key":"2983_CR12","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509\u201314.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"2983_CR13","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res"},{"key":"2983_CR14","doi-asserted-by":"crossref","unstructured":"Szklarczyk D, Nastou K, Koutrouli M, Kirsch R, Mehryary F, Hachilif R et al. The STRING database in 2025: protein networks with directionality of regulation. Nucleic Acids Res. 2024;gkae1113.","DOI":"10.1093\/nar\/gkae1113"},{"issue":"Database issue","key":"2983_CR15","first-page":"D258","volume":"32","author":"MA Harris","year":"2004","unstructured":"Harris MA, Clark J, Ireland A, Lomax J, Ashburner M, Foulger R, et al. The gene ontology (GO) database and informatics resource. Nucleic Acids Res. 2004;32(Database issue):D258\u2013261.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"2983_CR16","doi-asserted-by":"publisher","first-page":"D590","DOI":"10.1093\/nar\/gky962","volume":"47","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa M, Sato Y, Furumichi M, Morishima K, Tanabe M. New approach for Understanding genome variations in KEGG. Nucleic Acids Res. 2019;47(D1):D590\u20135.","journal-title":"Nucleic Acids Res"},{"issue":"43","key":"2983_CR17","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2983_CR18","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"key":"2983_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics. 2013;14:7.","journal-title":"BMC Bioinformatics"},{"issue":"6","key":"2983_CR20","doi-asserted-by":"publisher","first-page":"bbab260","DOI":"10.1093\/bib\/bbab260","volume":"22","author":"D Maeser","year":"2021","unstructured":"Maeser D, Gruener RF, Huang RS. OncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021;22(6):bbab260.","journal-title":"Brief Bioinform"},{"issue":"4","key":"2983_CR21","doi-asserted-by":"publisher","first-page":"573","DOI":"10.26502\/jbb.2642-91280119","volume":"6","author":"D Wang","year":"2023","unstructured":"Wang D, Qian X, Du YCN, Sanchez-Solana B, Chen K, Kanigicherla M, et al. cProSite: A web based interactive platform for online proteomics, phosphoproteomics, and genomics data analysis. J Biotechnol Biomed. 2023;6(4):573\u20138.","journal-title":"J Biotechnol Biomed"},{"issue":"3","key":"2983_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"2983_CR23","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1002\/cncr.35128","volume":"130","author":"TB Kratzer","year":"2024","unstructured":"Kratzer TB, Bandi P, Freedman ND, Smith RA, Travis WD, Jemal A, et al. Lung cancer statistics, 2023. Cancer. 2024;130(8):1330\u201348.","journal-title":"Cancer"},{"issue":"2","key":"2983_CR24","doi-asserted-by":"publisher","first-page":"e306","DOI":"10.1002\/onco.13586","volume":"26","author":"S Popat","year":"2021","unstructured":"Popat S, Navani N, Kerr KM, Smit EF, Batchelor TJP, Van Schil P, et al. Navigating diagnostic and treatment decisions in Non-Small cell lung cancer: expert commentary on the multidisciplinary team approach. Oncologist. 2021;26(2):e306\u201315.","journal-title":"Oncologist"},{"issue":"10454","key":"2983_CR25","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","volume":"404","author":"ML Meyer","year":"2024","unstructured":"Meyer ML, Fitzgerald BG, Paz-Ares L, Cappuzzo F, J\u00e4nne PA, Peters S, et al. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet. 2024;404(10454):803\u201322.","journal-title":"Lancet"},{"issue":"10258","key":"2983_CR26","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","volume":"396","author":"GBD 2019 Risk Factors Collaborators","year":"2020","unstructured":"GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1223\u201349.","journal-title":"Lancet"},{"issue":"15","key":"2983_CR27","doi-asserted-by":"publisher","first-page":"10147","DOI":"10.1074\/jbc.M708535200","volume":"283","author":"A Inforzato","year":"2008","unstructured":"Inforzato A, Rivieccio V, Morreale AP, Bastone A, Salustri A, Scarchilli L, et al. Structural characterization of PTX3 disulfide bond network and its multimeric status in cumulus matrix organization. J Biol Chem. 2008;283(15):10147\u201361.","journal-title":"J Biol Chem"},{"issue":"6","key":"2983_CR28","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1158\/0008-5472.CAN-09-2335","volume":"70","author":"G Germano","year":"2010","unstructured":"Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 2010;70(6):2235\u201344.","journal-title":"Cancer Res"},{"issue":"2","key":"2983_CR29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3324\/haematol.2010.031070","volume":"96","author":"T Barbui","year":"2011","unstructured":"Barbui T, Carobbio A, Finazzi G, Vannucchi AM, Barosi G, Antonioli E, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica. 2011;96(2):315\u20138.","journal-title":"Haematologica"},{"issue":"3","key":"2983_CR30","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/bjc.2013.348","volume":"109","author":"S Kondo","year":"2013","unstructured":"Kondo S, Ueno H, Hosoi H, Hashimoto J, Morizane C, Koizumi F, et al. Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma. Br J Cancer. 2013;109(3):739\u201346.","journal-title":"Br J Cancer"},{"issue":"1\u20132","key":"2983_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jneuroim.2013.04.009","volume":"260","author":"M Locatelli","year":"2013","unstructured":"Locatelli M, Ferrero S, Martinelli Boneschi F, Boiocchi L, Zavanone M, Maria Gaini S, et al. The long pentraxin PTX3 as a correlate of cancer-related inflammation and prognosis of malignancy in gliomas. J Neuroimmunol. 2013;260(1\u20132):99\u2013106.","journal-title":"J Neuroimmunol"},{"issue":"2","key":"2983_CR32","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/jvh.12472","volume":"23","author":"RF Carmo","year":"2016","unstructured":"Carmo RF, Aroucha D, Vasconcelos LRS, Pereira LMMB, Moura P, Cavalcanti MSM. Genetic variation in PTX3 and plasma levels associated with hepatocellular carcinoma in patients with HCV. J Viral Hepat. 2016;23(2):116\u201322.","journal-title":"J Viral Hepat"},{"issue":"4","key":"2983_CR33","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.cell.2015.01.004","volume":"160","author":"E Bonavita","year":"2015","unstructured":"Bonavita E, Gentile S, Rubino M, Maina V, Papait R, Kunderfranco P, et al. PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell. 2015;160(4):700\u201314.","journal-title":"Cell"},{"issue":"1","key":"2983_CR34","doi-asserted-by":"publisher","first-page":"18400","DOI":"10.1038\/s41598-020-75376-z","volume":"10","author":"G Stallone","year":"2020","unstructured":"Stallone G, Netti GS, Cormio L, Castellano G, Infante B, Pontrelli P, et al. Modulation of complement activation by pentraxin-3 in prostate cancer. Sci Rep. 2020;10(1):18400.","journal-title":"Sci Rep"},{"issue":"7","key":"2983_CR35","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.3390\/cancers13071611","volume":"13","author":"UG Falagario","year":"2021","unstructured":"Falagario UG, Busetto GM, Netti GS, Sanguedolce F, Selvaggio O, Infante B, et al. Prospective validation of Pentraxin-3 as a novel serum biomarker to predict the risk of prostate Cancer in patients scheduled for prostate biopsy. Cancers (Basel). 2021;13(7):1611.","journal-title":"Cancers (Basel)"},{"key":"2983_CR36","doi-asserted-by":"publisher","first-page":"29385","DOI":"10.1038\/srep29385","volume":"6","author":"TH Ying","year":"2016","unstructured":"Ying TH, Lee CH, Chiou HL, Yang SF, Lin CL, Hung CH, et al. Knockdown of pentraxin 3 suppresses tumorigenicity and metastasis of human cervical cancer cells. Sci Rep. 2016;6:29385.","journal-title":"Sci Rep"},{"issue":"2","key":"2983_CR37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccell.2015.07.002","volume":"28","author":"R Ronca","year":"2015","unstructured":"Ronca R, Giacomini A, Di Salle E, Coltrini D, Pagano K, Ragona L, et al. Long-Pentraxin 3 derivative as a Small-Molecule FGF trap for Cancer therapy. Cancer Cell. 2015;28(2):225\u201339.","journal-title":"Cancer Cell"},{"issue":"4","key":"2983_CR38","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/ijc.29822","volume":"138","author":"M Infante","year":"2016","unstructured":"Infante M, Allavena P, Garlanda C, Nebuloni M, Morenghi E, Rahal D, et al. Prognostic and diagnostic potential of local and Circulating levels of pentraxin 3 in lung cancer patients. Int J Cancer. 2016;138(4):983\u201391.","journal-title":"Int J Cancer"},{"issue":"2","key":"2983_CR39","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/path.4181","volume":"230","author":"R Ronca","year":"2013","unstructured":"Ronca R, Alessi P, Coltrini D, Di Salle E, Giacomini A, Leali D, et al. Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer. J Pathol. 2013;230(2):228\u201338.","journal-title":"J Pathol"},{"issue":"37","key":"2983_CR40","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.3748\/wjg.v17.i37.4225","volume":"17","author":"JX Wang","year":"2011","unstructured":"Wang JX, He YL, Zhu ST, Yang S, Zhang ST. Aberrant methylation of the 3q25 tumor suppressor gene PTX3 in human esophageal squamous cell carcinoma. World J Gastroenterol. 2011;17(37):4225\u201330.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"2983_CR41","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jtho.2016.01.015","volume":"11","author":"RM Bremnes","year":"2016","unstructured":"Bremnes RM, Busund LT, Kilv\u00e6r TL, Andersen S, Richardsen E, Paulsen EE, et al. The role of Tumor-Infiltrating lymphocytes in development, progression, and prognosis of Non-Small cell lung Cancer. J Thorac Oncol. 2016;11(6):789\u2013800.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2983_CR42","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12943-016-0551-1","volume":"15","author":"EA Marshall","year":"2016","unstructured":"Marshall EA, Ng KW, Kung SHY, Conway EM, Martinez VD, Halvorsen EC, et al. Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis. Mol Cancer. 2016;15(1):67.","journal-title":"Mol Cancer"},{"issue":"8","key":"2983_CR43","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","volume":"27","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27(8):1482\u201392.","journal-title":"Ann Oncol"},{"issue":"5","key":"2983_CR44","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/JTO.0b013e31816de28f","volume":"3","author":"R Lilenbaum","year":"2008","unstructured":"Lilenbaum R, Raez L, Tseng J, Seigel L, Davila E. Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer. J Thorac Oncol. 2008;3(5):511\u20135.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2983_CR45","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.lungcan.2012.01.014","volume":"77","author":"O Mir","year":"2012","unstructured":"Mir O, Boudou-Rouquette P, Giroux J, Chapron J, Alexandre J, Gibault L, et al. Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer. Lung Cancer. 2012;77(1):104\u20139.","journal-title":"Lung Cancer"},{"issue":"6","key":"2983_CR46","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/annonc\/mdh215","volume":"15","author":"JD Winegarden","year":"2004","unstructured":"Winegarden JD, Mauer AM, Otterson GA, Rudin CM, Villalona-Calero MA, Lanzotti VJ, et al. A phase II study of oxaliplatin and Paclitaxel in patients with advanced non-small-cell lung cancer. Ann Oncol. 2004;15(6):915\u201320.","journal-title":"Ann Oncol"},{"issue":"2","key":"2983_CR47","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/labinvest.2013.147","volume":"94","author":"MD Siegelin","year":"2014","unstructured":"Siegelin MD, Borczuk AC. Epidermal growth factor receptor mutations in lung adenocarcinoma. Lab Invest. 2014;94(2):129\u201337.","journal-title":"Lab Invest"},{"issue":"6","key":"2983_CR48","doi-asserted-by":"publisher","first-page":"188967","DOI":"10.1016\/j.bbcan.2023.188967","volume":"1878","author":"S Singh","year":"2023","unstructured":"Singh S, Sadhukhan S, Sonawane A. 20 years since the approval of first EGFR-TKI, gefitinib: insight and foresight. Biochim Biophys Acta Rev Cancer. 2023;1878(6):188967.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"7","key":"2983_CR49","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s41417-021-00383-9","volume":"29","author":"J Liu","year":"2022","unstructured":"Liu J, Kang R, Tang D. The KRAS-G12C inhibitor: activity and resistance. Cancer Gene Ther. 2022;29(7):875\u20138.","journal-title":"Cancer Gene Ther"},{"issue":"10378","key":"2983_CR50","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","volume":"401","author":"AJ de Langen","year":"2023","unstructured":"de Langen AJ, Johnson ML, Mazieres J, Dingemans AMC, Mountzios G, Pless M, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet. 2023;401(10378):733\u201346.","journal-title":"Lancet"},{"issue":"7","key":"2983_CR51","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jtho.2023.03.015","volume":"18","author":"Z Li","year":"2023","unstructured":"Li Z, Song Z, Zhao Y, Wang P, Jiang L, Gong Y, et al. D-1553 (Garsorasib), a potent and selective inhibitor of KRASG12C in patients with NSCLC: phase 1 study results. J Thorac Oncol. 2023;18(7):940\u201351.","journal-title":"J Thorac Oncol"},{"key":"2983_CR52","doi-asserted-by":"publisher","first-page":"114527","DOI":"10.1016\/j.biopha.2023.114527","volume":"161","author":"M Tariq","year":"2023","unstructured":"Tariq M, Hussain N, Rehman K, Akash MSH, Al Haddad AHI, Said ASA, et al. Macrophages M2 polarization is involved in lapatinib-mediated chemopreventive effects in the lung cancer. Biomed Pharmacother. 2023;161:114527.","journal-title":"Biomed Pharmacother"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02983-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02983-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02983-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T19:02:30Z","timestamp":1750359750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02983-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2983"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02983-5","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,19]]},"assertion":[{"value":"9 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The Ethics Committee of China Medical University People\u2019s Hospital evaluated and approved this work (approval number 2024-K069). Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"1158"}}